For three decades, medical cannabis patients, states, healthcare professionals, and researchers have developed regulated medical cannabis programs and the clinical experience and scientific evidence necessary for federal recognition of cannabis as medicine. Congress supported this progress by protecting state programs from federal interference and removing longstanding research barriers. Together, the lessons learned from state programs and changes to international drug treaties recognizing cannabis' medical value have established a new pathway for federal regulation of medical cannabis.
In April 2026, Attorney General Order No. 6754-2026 placed qualifying medical cannabis products in Schedule III and established a federal registration pathway. However, federal recognition has not ended discrimination against patients or established a national medical cannabis program. Outdated federal policies continue to restrict access to healthcare, housing, employment, veterans' services, and other benefits and protections. Congress must address these discriminatory policies rather than leave patients experiencing harm to seek relief individually through the courts.
The FY2027 appropriations process gives Congress an immediate opportunity to act. Americans for Safe Access (ASA) is calling on seven appropriations subcommittees to protect patients, direct federal agencies to end discriminatory policies, strengthen product safety and research, and prepare for the integration of cannabis medicines into American healthcare.
DOWNLOAD SENATE APPROPS OVERVIEW | TAKE ACTION
PATIENT PRIORITIES. CONGRESSIONAL ACTION: FY2027 APPROPRIATIONS REQUESTS BY SUBCOMMITTEE |
COMMERCE, JUSTICE, SCIENCE, & RELATED AGENCIES
Retain the Medical Cannabis CJS Amendment; remove anti-rescheduling provisions; require DOJ guidance addressing ADA, Fair Housing Act, and Section 504 protections and individualized review. Require equitable, transparent DEA registration decisions, reporting, and oversight of the medical supply chain.
Detailed appropriations language: CJS
LABOR, HEALTH & HUMAN SERVICES, EDUCATION, & RELATED AGENCIES
Require HHS/CMS guidance preventing categorical denial of care or medical cannabis documentation across hospitals, hospices, nursing homes, assisted living facilities, FQHCs, transplant and pain programs, and Medicare/Medicaid providers. Require standard medical cannabis data fields, coverage and cost studies, and an HHS Office of Medical Cannabis and Cannabinoid Control.
Detailed appropriations language: HHS
TRANSPORTATION, HOUSING & URBAN DEVELOPMENT, & RELATED AGENCIES
Direct HUD to withdraw and replace outdated medical cannabis housing guidance. Address denial of admission, eviction, termination of assistance, lease nonrenewal, and refusal of reasonable accommodation based solely on participation in a state medical cannabis program, consistent with applicable federal law.
Detailed appropriations language: HUD
AGRICULTURE, RURAL DEVELOPMENT, FOOD & DRUG ADMINISTRATION, & RELATED AGENCIES
Require FDA labeling and safety disclosures for hemp-derived cannabinoids, medical cannabis testing and product-safety standards, adverse-event data and real-world evidence reporting. Address patient safety and access during the federal hemp transition.
Detailed appropriations language: Agriculture/FDA
MILITARY CONSTRUCTION, VETERANS AFFAIRS, & RELATED AGENCIES
Direct VA to replace VHA Directive 1315 to allow clinician discussion, state-law-permitted recommendations, referrals, completion of state forms, and clinical documentation. Require a report on veterans' access, integration into care, and potential costs or savings.
Detailed appropriations language: Military Construction/VA
FINANCIAL SERVICES & GENERAL GOVERNMENT
Require OPM policy review, coordinated with HHS, SAMHSA, and DOJ, so a cannabis-positive test alone is not treated as proof of on-duty impairment, misconduct, or unfitness without individualized, job-related evidence.
Detailed appropriations language: Financial Services
DEPARTMENT OF DEFENSE
Require DOD review of cannabis, hemp-derived cannabinoid, CBD, and medical disclosure rules. Establish appropriate clinical-review pathways for service members that account for readiness, actual safety risks, disability evaluation, transitions, and continuity of care.
Detailed appropriations language: Defense
THE WINDOW FOR CONGRESSIONAL ACTION IS NOW |
As Congress works to finalize FY2027 appropriations before the current continuing resolution expires on December 11, 2026, Americans for Safe Access is urging lawmakers to include provisions that end discriminatory federal policies, protect medical cannabis patients, and address the gaps left by the Attorney General's order.
Although the April 2026 order represents a significant shift in federal cannabis policy, it has not established a comprehensive national medical cannabis program or resolved the barriers patients continue to face in healthcare, housing, employment, and other federally regulated settings. Congress can address these gaps through appropriations language that directs federal agencies to take specific actions within their existing authority, strengthens congressional oversight, and establishes greater accountability for implementing medical cannabis policies.
ASA's FY2027 recommendations span seven appropriations subcommittees and focus on maintaining patient access during the federal transition, protecting patients from discrimination, strengthening product safety standards and research, improving veterans' healthcare, and ensuring DOJ and DEA implement federal registration requirements fairly and transparently. ASA is also urging Congress to preserve the longstanding medical cannabis appropriations amendment and ensure that the additional restrictions included in the House CJS proposal remain excluded from the final funding legislation.
These actions can provide immediate protections while laying the groundwork for comprehensive legislation in the 120th Congress. ASA's long-term goal remains a federal framework that builds on decades of state medical cannabis experience, recognizes cannabis' therapeutic potential, and integrates medical cannabis into the American healthcare system through consistent standards, meaningful patient protections, and equitable access.
The Path Forward: The Medical Cannabis & Cannabinoid Act | TAKE ACTION
BACKGROUND & SUPPORTING DOCUMENTSFor the complete historical, scientific, and treaty-based argument, see ASA’s companion blog: “From State Medical Cannabis Programs to National Healthcare Integration: Why Congress Must Act Now.” Attorney General Order No. 6754-2026 DEA Marijuana Rescheduling Regulatory Actions Congressional Research Service: Federal Hemp Definition Changes, October 28, 2026 |
FY2027 CONGRESSIONAL APPROPRIATIONS UPDATES |
NOVEMBER 10, 2026 UPDATE
Senate Releases Agriculture/FDA and Military Construction/VA Funding BillsOn November 10, the Senate Appropriations Committee released its FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies bill and Military Construction, Veterans Affairs, and Related Agencies bill, along with accompanying explanatory statements. The proposals include provisions addressing hemp regulation, cannabinoid research, FDA oversight, and medical marijuana research within the Department of Veterans Affairs. However, these provisions do not resolve the broader gaps in patient access, product safety standards, or the integration of medical cannabis into federal healthcare programs. Americans for Safe Access (ASA) is urging Congress to strengthen these proposals by directing FDA to advance medical cannabis testing, labeling, and product safety standards; assess the loss of patient access resulting from changes to federal hemp law; and expand research and real-world evidence. ASA is also calling for VA to update outdated policies restricting medical cannabis recommendations, documentation, referrals, and care coordination, while expanding research into therapeutic outcomes and costs. These recommendations would help ensure that federal funding decisions reflect the medical needs of patients and veterans. Senate Appropriations Committee: November 10 Announcement, Bill Texts, and Explanatory Statements ASA's Detailed Recommendations: Agriculture/FDA Appropriations | Military Construction/VA Appropriations |
NOVEMBER 12, 2026 UPDATE
Senate Retains Medical Cannabis Protections and Omits Restrictive House Provisions in FY2027 CJS ProposalOn November 12, the Senate Appropriations Committee released five additional FY2027 funding bills covering Commerce, Justice, Science; Energy and Water Development; Homeland Security; Interior and Environment; and the Legislative Branch. The Commerce, Justice, Science (CJS) proposal is particularly significant for medical cannabis patients because it retains the longstanding appropriations protection for state medical cannabis programs, including Nebraska, while omitting two concerning provisions included in the House version. Americans for Safe Access (ASA) is encouraged that the Senate's initial FY2027 CJS draft omits the House's anti-rescheduling provision and additional language expressly preserving enhanced federal drug penalties near schools and other protected locations. Although the Senate Appropriations Committee has not yet voted on the proposal, the absence of these provisions is a welcome starting point. ASA urges committee members to maintain their exclusion as the legislation advances and calls on congressional negotiators to ensure they are not reintroduced when the House and Senate reconcile their funding proposals. Preserving the medical cannabis CJS amendment without these additional restrictions would help protect progress toward federal recognition and regulation of cannabis as medicine. While these developments represent progress, additional congressional direction is necessary to address patient discrimination, federal registration decisions, and the availability of medical cannabis through federally compliant supply chains. ASA is urging Congress to require DOJ guidance addressing discriminatory federal policies and to establish greater transparency and accountability in DEA's implementation of the Attorney General's April 2026 order. ASA is also requesting that DOJ and DEA report on how they intend to meet patients' medical cannabis access needs as federal registrations are issued, particularly in states with combined medical and adult-use licensing and jurisdictions where DEA identifies conflicts with federal law or international treaty obligations. This reporting should explain how DOJ and DEA will work with states, territories, and the District of Columbia to resolve regulatory conflicts, provide opportunities for corrective action, and address continuity of lawful patient access while preventing diversion. Senate Appropriations Committee: November 12 Announcement, Bill Texts, and Explanatory Statements ASA's Detailed Recommendations: Commerce, Justice, Science FY2027 Appropriations |
NOVEMBER 16, 2026 UPDATE
Senate Releases Final Five FY2027 Funding Proposals, Opening Additional Opportunities for Medical Cannabis Patient ProtectionsOn November 16, the Senate Appropriations Committee released its final five FY2027 funding proposals, covering Defense; Financial Services and General Government; Labor, Health and Human Services, Education; Transportation, Housing and Urban Development; and State and Foreign Operations. With all twelve Senate appropriations proposals now released, Congress has an opportunity to address medical cannabis patient protections across federal agencies as lawmakers negotiate final funding legislation. Four of the newly released proposals are particularly relevant to Americans for Safe Access' (ASA) FY2027 recommendations. The Labor, Health and Human Services proposal provides an opportunity to direct HHS and CMS to update healthcare guidance, improve medical cannabis documentation, evaluate insurance coverage, and establish coordinated federal medical cannabis oversight. The Transportation and Housing proposal offers an opportunity to require HUD to revise outdated policies that can leave state-authorized medical cannabis patients vulnerable to housing exclusions. Through Financial Services and General Government appropriations, ASA is requesting that Congress direct the Office of Personnel Management to review federal workplace policies that treat cannabis-positive drug tests as evidence of impairment without individualized assessment. Defense appropriations provide an opportunity to review medical cannabis and cannabinoid policies affecting service members, including clinical consultation, safety requirements, and continuity of care. Although the Senate has now released its complete set of FY2027 funding proposals, these drafts have not been enacted, and additional congressional action is needed to address the federal policies that continue to discriminate against medical cannabis patients. ASA is urging Senate appropriators to incorporate its recommendations into final legislation or accompanying committee report language, while preserving the medical cannabis protections included in the Senate's November 12 Commerce, Justice, Science proposal. With the current continuing resolution expiring December 11, Congress has a limited window to address these gaps. The federal government's recognition of cannabis as medicine must be followed by policies that protect patients, support healthcare integration, and ensure that federal agencies fulfill their responsibilities during the transition. Senate Appropriations Committee: November 16 Announcement, Bill Texts, and Explanatory Statements ASA's Detailed Recommendations: Labor, Health and Human Services | Transportation and HUD | Financial Services and General Government | Defense |
Share this page